5-methoxy-1-(trifluoromethyl)-2,3-dihydro-1H-inden-1-ol | 188726-17-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5-methoxy-1-(trifluoromethyl)-2,3-dihydro-1H-inden-1-ol
• 英文别名: 1-Hydroxy-5-methoxy-1-(trifluoromethyl)indan；5-methoxy-1-(trifluoromethyl)-2,3-dihydroinden-1-ol
• CAS: 188726-17-2
• 化学式: C₁₁H₁₁F₃O₂
• 分子量: 232.202
• InChiKey: ITSJGTVWYFIFMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-methoxy-1-(trifluoromethyl)-2,3-dihydro-1H-inden-1-ol 在 四氯化钛 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成
  参考文献：
  名称：

  Discovery and stereoselective synthesis of the novel isochroman neurokinin-1 receptor antagonist ‘CJ-17,493’

  摘要：

  A novel central nervous system (CNS) selective neurokinin-1 (NK1) receptor antagonist, (2S, 3S)-3-[(1R)-6-methoxy- 1-methyl-1-trifluoromethylisochroman-7-yl]-methylamino-2-phenylpiperidine 'CJ-17,493'( compound (+)-1), was synthesized stereoselectively using a kinetic resolution by lipase-PS as a key step. Compound (+)-1 displayed high and selective affinity (K-i = 0.2 nM) for the human NK1 receptor in IM-9 cells, potent activity in the [Sar(9), Met(O-2)(11)] SP-induced gerbil tapping model (ED50 = 0.04 mg/kg, sc) and in the ferret cisplatin (10 mg/kg, ip)-induced anti-emetic activity model (vomiting: ED90 = 0.07 mg/kg, sc), all levels of activity comparable with those of CP-122,721. In addition, compound (+)-1 exhibited linear pharmacokinetics rather than the super dose-proportionality of CP-122,721 and this result provides a potential solution for the clinical issue observed with CP-122,721. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.06.047
• 作为产物：
  描述：

  5-甲氧基-1-茚酮 、 (三氟甲基)三甲基硅烷 在 四丁基氟化铵 、 盐酸 作用下， 以 四氢呋喃 为溶剂， 生成 5-methoxy-1-(trifluoromethyl)-2,3-dihydro-1H-inden-1-ol
  参考文献：
  名称：

  Discovery and stereoselective synthesis of the novel isochroman neurokinin-1 receptor antagonist ‘CJ-17,493’

  摘要：

  A novel central nervous system (CNS) selective neurokinin-1 (NK1) receptor antagonist, (2S, 3S)-3-[(1R)-6-methoxy- 1-methyl-1-trifluoromethylisochroman-7-yl]-methylamino-2-phenylpiperidine 'CJ-17,493'( compound (+)-1), was synthesized stereoselectively using a kinetic resolution by lipase-PS as a key step. Compound (+)-1 displayed high and selective affinity (K-i = 0.2 nM) for the human NK1 receptor in IM-9 cells, potent activity in the [Sar(9), Met(O-2)(11)] SP-induced gerbil tapping model (ED50 = 0.04 mg/kg, sc) and in the ferret cisplatin (10 mg/kg, ip)-induced anti-emetic activity model (vomiting: ED90 = 0.07 mg/kg, sc), all levels of activity comparable with those of CP-122,721. In addition, compound (+)-1 exhibited linear pharmacokinetics rather than the super dose-proportionality of CP-122,721 and this result provides a potential solution for the clinical issue observed with CP-122,721. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.06.047

文献信息

• Substituted benzylaminopiperidine compounds
  申请人：Pfizer Inc.

  公开号：US06329396B1

  公开（公告）日：2001-12-11

  The invention provides a substituted benzylaminopiperidine compounds that are useful in the treatment of gastrointestinal disorders; central nervous system (CNS) disorders; inflammatory disease; emesis; urinary incontinence; pain; migraine; sunburn; diseases, disorders and adverse conditions caused by Heliobacter pylori; or angiogenesis, especially CNS disorders in a mammalian subject, especially in humans.

  这项发明提供了一种取代苄基氨基哌啶化合物，可用于治疗胃肠道疾病；中枢神经系统（CNS）疾病；炎症性疾病；呕吐；尿失禁；疼痛；偏头痛；晒伤；由幽门螺杆菌引起的疾病、疾病和不良症状；或血管生成，尤其是在哺乳动物主体中的中枢神经系统疾病，尤其是在人类中。
• Substituted benzylamino piperidine compounds
  申请人：PFIZER INC.

  公开号：EP1114817A1

  公开（公告）日：2001-07-11

  This invention provides a compound of formula (I) and its pharmaceutically acceptable salts wherein R is halo C1-C8 alkyl, halo C2-C8 alkenyl, halo C2-C8 alkynyl or halo C1-C8 alkyl substituted by hydroxy or C1-C8 alkoxy; R1 is hydrogen, halo or C1-C6 alkoxy; or R and R1, together with two carbon atoms shared between the benzene ring and the R and R1, complete a fused C4-C6 cycloakyl wherein one carbon atom is optionally replaced by oxygen and wherein one or two of the carbon atoms are optionally substituted by up to five substituents selected from halo, C1-C6 alkyl and halo C1-C6 alkyl; X is C1-C6 alkoxy, halo C1-C6 alkoxy, phenoxy or halo; and Ar is phenyl optionally substituted by halo. These compounds are of use in treating a gastrointestinal disorder, a central nervous system (CNS) disorder, an inflammatory disease, emesis, urinary incontinence, pain, migraine, sunburn, diseases, disorders and adverse conditions caused by Helicobacter pylori or an angiogenesis especially CNS disorders in a mammalian subject, especially humans.

  本发明提供了式 (I) 的化合物及其药学上可接受的盐类 其中 R 是卤代 C1-C8 烷基、卤代 C2-C8 烯基、卤代 C2-C8 烷炔基或被羟基或 C1-C8 烷氧基取代的卤代 C1-C8 烷基；R1 是氢、卤代或 C1-C6 烷氧基；或 R 和 R1，连同苯环与 R 和 R1 之间共用的两个碳原子，组成一个融合的 C4-C6 环烷基，其中一个碳原子任选被氧取代，并且其中一个或两个碳原子任选被最多五个选自卤代、C1-C6 烷基和卤代 C1-C6 烷基的取代基取代；X 是 C1-C6 烷氧基、卤代 C1-C6 烷氧基、苯氧基或卤代；Ar 是任选被卤代取代的苯基。这些化合物可用于治疗胃肠道疾病、中枢神经系统（CNS）疾病、炎症、呕吐、尿失禁、疼痛、偏头痛、晒伤、幽门螺杆菌引起的疾病、失调和不良状况或血管生成，尤其是哺乳动物，特别是人类的中枢神经系统疾病。
• Synthesis of aromatic compounds containing a 1,1-dialkyl-2-trifluoromethyl group, a bioisostere of the tert-alkyl moiety
  作者：Hirotaka Tanaka、Yuji Shishido

  DOI：10.1016/j.bmcl.2007.09.053

  日期：2007.11

  1,1-Dialkyl-2-perfluoroalkyl compounds, which are potential metabolically stable bioisosteres of the tert-alkyl moiety, have been synthesized from the corresponding tertiary alcohols using titanium (IV) chloride-dimethylzinc or trimethylaluminium as the source of the methyl group. The synthetic methods proved to be versatile for synthesizing 1,1-dimethyl-2,2,2-trifluoroethyl compounds and analogs, including compounds containing aromatic and heterocyclic rings. (C) 2007 Elsevier Ltd. All rights reserved.
• SUBSTITUTED BENZYLAMINOPIPERIDINE COMPOUNDS
  申请人：PFIZER INC.

  公开号：EP0861235A1

  公开（公告）日：1998-09-02
• US6329396B1
  申请人：——

  公开号：US6329396B1

  公开（公告）日：2001-12-11